Global Information
회사소개 | 문의 | 위시리스트

인간 마이크로바이옴 모듈레이터 시장 분석과 예측 : 주요 15개국의 데이터, 파이프라인 제품 지도제작, 경쟁 구도(2018-2023년)

Global Human Microbiome Modulators Market: Focus on Non-Dairy Supplements, Drugs, Applications, 15 Countries Data, Pipeline Product Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2023

리서치사 BIS Research Inc.
발행일 2018년 12월 상품 코드 755517
페이지 정보 영문
가격
US $ 5,000 ₩ 5,977,000 Unprintable PDF by E-mail (Single User License)
US $ 5,500 ₩ 6,574,000 Hard Copy
US $ 6,500 ₩ 7,770,000 Printable PDF by E-mail (Single Site License)
US $ 8,000 ₩ 9,563,000 Printable PDF and Excel by E-mail (Enterprise-wide License)


인간 마이크로바이옴 모듈레이터 시장 분석과 예측 : 주요 15개국의 데이터, 파이프라인 제품 지도제작, 경쟁 구도(2018-2023년) Global Human Microbiome Modulators Market: Focus on Non-Dairy Supplements, Drugs, Applications, 15 Countries Data, Pipeline Product Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2023
발행일 : 2018년 12월 페이지 정보 : 영문

세계의 인간 마이크로바이옴 모듈레이터(Human Microbiome Modulators) 시장 규모는 2023년까지 27억 9,000만 달러에 달할 전망입니다.

세계의 인간 마이크로바이옴 모듈레이터 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 및 시장 기회 분석, 경쟁 분석, 규제 동향, 제품·용도·지역/주요 국가별 동향과 시장 규모의 추이와 예측, 주요 기업 개요 등을 정리하여 전해드립니다.

개요

제1장 시장 개요

  • 인간 마이크로바이옴 모듈레이터의 분류
  • 인간 마이크로바이옴 모듈레이터의 역사적 전망
  • 인간 마이크로바이옴 프로젝트
  • 마이크로바이옴의 인간 생리학에 대한 영향
  • 세계의 발자국
  • 인간 마이크로바이옴 모듈레이터 : 향후 가능성

제2장 시장 역학

  • 개요
  • 빙산 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제3장 경쟁 분석

  • 주요 전략·발전
  • 시장 점유율 분석
  • 성장 점유율 분석
  • 산업의 매력
  • 제품 파이프라인 분석

제4장 규제 프레임워크

  • 미국의 법률 요건·프레임워크
  • 유럽의 법률 요건·프레임워크
  • 아시아태평양의 법률 요건·프레임워크
  • 세계의 마이크로바이옴 컨소시엄

제5장 세계의 인간 마이크로바이옴 모듈레이터 시장 : 제품별

  • 개요
  • 프로바이오틱스·크림
  • 프로바이오틱스·식이보충제
  • 의약품

제6장 세계의 인간 마이크로바이옴 모듈레이터 시장 : 용도별

  • 개요
  • 위장 건강
  • 면역 건강
  • 여성 건강
  • 구강 건강
  • 기타

제7장 세계의 인간 마이크로바이옴 모듈레이터 시장 : 지역별

  • 각국의 성장 가능성 분석
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 기타

제8장 기업 개요

  • 개요
  • Bayer AG
  • BioGaia AB
  • Chr. Hansen Holding A/S
  • DowDuPont Inc.
  • Garden of Life, LLC.
  • Ingredion Incorporated
  • ISOThrive LLC
  • Jarrow Formulas, Inc.
  • Koninklijke DSM N.V.
  • Lallemand Inc.
  • MicroBiome Therapeutics, LLC
  • Pharmavite LLC
  • Probi AB
  • Probiotics International Limited(ADM Protexin)
  • Quorum Innovations, LLC
  • Sanofi S.A.
  • The Procter and Gamble Company
  • Yakult Honsha Co., Ltd.

제9장 조사 범위·조사 방법

KSA 18.12.19

List of Tables

  • Table 2.1 Impact Analysis of Market Drivers
  • Table 2.2 Impact Analysis of Market Restraints
  • Table 3.1 R&D Expenditure of Major Human Microbiome Therapeutic Companies (as of FY2017)
  • Table 4.1 Global Microbiome Consortiums and Their Participants
  • Table 6.1 Documented Microbial Associations with Disease Status

List of Figures

  • Figure 1 Antibiotic Resistance (%) in OECD Countries, 2014
  • Figure 2 Global Value of Precision Medicine Within Healthcare, 2016 and 2020
  • Figure 3 Impact Analysis of Market Drivers and Market Restraints, 2018-2023
  • Figure 4 Global Human Microbiome Modulators Market Snapshot
  • Figure 5 Dominating Segments of Global Human Microbiome Modulators Market, 2017 and 2023
  • Figure 6 Global Human Microbiome Modulators Market (by Products), 2017 and 2023
  • Figure 7 Global Human Microbiome Modulators Market (by Application), 2017 and 2023
  • Figure 8 Global Human Microbiome Modulator Market (by Region), 2017 and 2023
  • Figure 9 Pipeline Analysis
  • Figure 10 Vital Strategies Incorporated by Key Players in the Global Human Microbiome Modulators Market
  • Figure 11 Market Statistics
  • Figure 12 Market Share Analysis for the Global Human Microbiome Modulators Market, 2017
  • Figure 1.1 Classification of Human Microbiome Modulators
  • Figure 1.2 Evolution of Human Microbiome Modulators
  • Figure 1.3 Significant Milestones from the HMP (Phase 1)
  • Figure 1.4 Global Human Microbiome Modulators Market, 2017-2023
  • Figure 2.1 Iceberg Analysis
  • Figure 2.2 Projected Global Geriatric Population (in billion), 1900-2100
  • Figure 2.3 Global Deaths Per Year By Cause (WHO), 2016
  • Figure 2.4 Average Healthcare Expenditure (by OECD Countries), 2015
  • Figure 3.1 Share of Key Developments and Strategies, January 2014-August 2018
  • Figure 3.2 Agreement, Collaboration, and Partnership Share (by Companies), January 2014-August 2018
  • Figure 3.3 Funding and Expansion Activities Share (by Companies), January 2014-August 2018
  • Figure 3.4 Product Launches Share (by Companies), January 2014-August 2018
  • Figure 3.5 Merger and Acquisition Share (by Companies), January 2014-August 2018
  • Figure 3.6 Product Approval Share (by Companies), January 2014-August 2018
  • Figure 3.7 Market Share Analysis for the Global Human Micorbiome Modulators Market, 2016
  • Figure 3.8 Market Share Analysis for Global Human Microbiome Modulators Market, 2017
  • Figure 3.9 Growth Share Matrix for Global Human Microbiome Modulators Market (by Application), 2017
  • Figure 3.10 Growth Share Matrix for Global Human Microbiome Modulators Market (by Company), 2017
  • Figure 3.11 Growth Share Matrix for Global Human Microbiome Modulators Market (by Country), 2017
  • Figure 3.12 Industy Attractiveness (Porter's Five Forces Analysis)
  • Figure 3.13 Bargaining Power of Suppliers: Overall Impact
  • Figure 3.14 Bargaining Power of Buyers: Overall Impact
  • Figure 3.15 Threat of New Entrants: Overall Impact
  • Figure 3.16 Threat of Substitute Products: Overall Impact
  • Figure 3.17 Intensity of Competitive Rivalry: Overall Impact
  • Figure 3.18 Pipeline Analysis
  • Figure 3.19 Distribution of Pipeline Products According to Their Development Stage
  • Figure 4.1 Guidelines for the Evaluation of Probiotics for Food Use
  • Figure 4.2 Guidelines for the Chemistry, Manufacturing, and Control of LBPs by the FDA, 2016
  • Figure 4.3 Guidelines on the Scientific Requirements for Health Claims by the EFSA (2015)
  • Figure 4.4 Guidelines by the CFDA for Approval of Health Foods
  • Figure 5.1 Human Microbiome Modulators Market (by Product)
  • Figure 5.2 Global Human Microbiome Modulators Market (by Product), 2017 and 2023
  • Figure 5.3 Mechanism of Action of Probiotic in the Gut Microbiome
  • Figure 5.4 Global Human Microbiome Modulators Market (by Probiotics and Creams), 2017-2023
  • Figure 5.5 Effects of Prebiotics in Human Body
  • Figure 5.6 Global Human Microbiome Modulators Market (by Prebiotics and Dietary Supplements), 2017-2023
  • Figure 5.7 Mechanisms of Action of Human Microbiome Therapeutic Drugs
  • Figure 5.8 Number of Drugs in Active Development, 2011-2017
  • Figure 5.9 Global Human Microbiome Modulators Market (by Drugs), 2017-2023
  • Figure 6.1 Global Human Microbiome Modulators Market (by Application), 2017 and 2023
  • Figure 6.2 Global Human Microbiome Modulators Market (by Digestive Health), 2017-2023
  • Figure 6.3 Total Market Size for Digestive Health-related Modulators (2017-2023)
  • Figure 6.4 Interdepending Regulators of the Immune System
  • Figure 6.5 Global Human Microbiome Modulators Market (by Immune Health), 2017-2023
  • Figure 6.6 Total Market Size for Immune Health-related Modulators (2017-2023)
  • Figure 6.7 Inter-related Factors Governing Women's Health
  • Figure 6.8 Global Human Microbiome Modulators Market (by Women's Health), 2017-2023
  • Figure 6.9 Total Market Size for Women's Health-related Modulators (2017-2023)
  • Figure 6.10 Ecological Shifts in the Oral Microbiome Causing a Diseased Oral Cavity
  • Figure 6.11 Global Human Microbiome Modulators Market (by Oral Health), 2017-2023
  • Figure 6.12 Total Market Size for Oral Health-related Modulators (2017-2023)
  • Figure 6.13 Global Human Microbiome Modulators Market (by Other Health Applications), 2017-2023
  • Figure 6.14 Total Market Size for Other Health-related Modulators, 2017-2023
  • Figure 7.1 Global Human Microbiome Modulators Market Scenario, 2017 and 2023
  • Figure 7.2 Global Human Microbiome Modulators (by Region), 2017-2023
  • Figure 7.3 Analysis of Growth Potential (by Countries)
  • Figure 7.4 North America: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.5 North America: Market Dynamics
  • Figure 7.6 North America: Human Microbiome Modulators Market (by Country), 2017 and 2023
  • Figure 7.7 The U.S: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.8 Canada: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.9 Europe: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.10 Europe: Market Dynamics
  • Figure 7.11 Europe: Human Microbiome Modulators Market (by Country), 2017 and 2023
  • Figure 7.12 Italy: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.13 Russia: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.14 France: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.15 Poland: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.16 Germany: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.17 The U.K.: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.18 Rest-of-Europe: Human Micorbiome Modulators Market, 2017-2023
  • Figure 7.19 Asia-Pacific: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.20 Asia-Pacific: Market Dynamics
  • Figure 7.21 Asia Pacific: Human Microbiome Modulators Market (by Country), 2017 and 2023
  • Figure 7.22 Japan: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.23 Australia: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.24 South Korea: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.25 China: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.26 India: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.27 Rest-of-Asia Pacific: Human Micorbiome Modulators Market, 2017-2023
  • Figure 7.28 Latin America: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.29 Latin America: Market Dynamics
  • Figure 7.30 Latin America: Human Microbiome Modulators Market (by Country), 2017 and 2023
  • Figure 7.31 Brazil: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.32 Mexico: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.33 Rest-of-Latin America: Human Microbiome Modulators Market, 2017-2023
  • Figure 7.34 Rest-of-the-World: Human Microbiome Modulators Market, 2017-2023
  • Figure 8.1 Total Number of Companies Profiled
  • Figure 8.2 Bayer AG: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.3 Bayer AG: Overall Financials, 2015-2017
  • Figure 8.4 Bayer AG: Revenue (by Segment), 2015-2017
  • Figure 8.5 Bayer AG: Revenue (by Region), 2015-2017
  • Figure 8.6 Bayer AG: R&D Expenditure, 2015-2017
  • Figure 8.7 Bayer AG: Global Presence, 2015-2017
  • Figure 8.8 Bayer AG: SWOT Analysis
  • Figure 8.9 BioGaia AB: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.10 BioGaia AB: Overall Financials, 2015-2017
  • Figure 8.11 BioGaia AB: Revenue (by Segment), 2015-2017
  • Figure 8.12 BioGaia AB: Revenue (by Region), 2015-2017
  • Figure 8.13 BioGaia AB: R&D Expenditure, 2015-2017
  • Figure 8.14 BioGaia AB: Revenue Forecast, 2015-2020
  • Figure 8.15 BioGaia AB: Global Presence, 2015-2017
  • Figure 8.16 BioGaia AB: SWOT Analysis
  • Figure 8.17 Chr. Hansen Holding A/S: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.18 Chr. Hansen Holding A/S: Overall Financials, 2015-2017
  • Figure 8.19 Chr. Hansen Holding A/S: Revenue (by Segment), 2015-2017
  • Figure 8.20 Chr. Hansen Holding A/S: Revenue (by Region), 2015-2017
  • Figure 8.21 Chr. Hansen Holding A/S: R&D Expenditure, 2015-2017
  • Figure 8.22 Chr. Hansen Holding A/S: Revenue Forecast, 2015-2020
  • Figure 8.23 Chr. Hansen Holding A/S: Global Presence, 2015-2017
  • Figure 8.24 Chr. Hansen Holding A/S: SWOT Analysis
  • Figure 8.25 DowDuPont Inc.: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.26 DowDuPont Inc.: Overall Financials, 2015-2017
  • Figure 8.27 DowDuPont Inc.: Revenue (by Segment), 2015-2017
  • Figure 8.28 DowDuPont Inc.: Revenue (by Region), 2015-2017
  • Figure 8.29 DowDuPont Inc.: R&D Expenditure, 2015-2017
  • Figure 8.30 DowDuPont Inc.: Global Presence, 2015-2017
  • Figure 8.31 DowDuPont Inc.: SWOT Analysis
  • Figure 8.32 Garden of Life, LLC.: Overall Product Portfolio
  • Figure 8.33 Garden of Life, LLC.: SWOT Analysis
  • Figure 8.34 Ingredion Incorporated: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.35 Ingredion Incorporated: Overall Financials, 2015-2017
  • Figure 8.36 Ingredion Incorporated: Revenue (by Segment), 2015-2017
  • Figure 8.37 Ingredion Incorporated: Revenue (by Region), 2015-2017
  • Figure 8.38 Ingredion Incorporated: R&D Expenditure, 2015-2017
  • Figure 8.39 Ingredion Incorporated: Revenue Forecast, 2015-2020
  • Figure 8.40 Ingredion Incorporated: Global Presence, 2015-2017
  • Figure 8.41 Ingredion Incorporated: SWOT Analysis
  • Figure 8.42 ISOThrive LLC.: Overall Product Portfolio
  • Figure 8.43 ISOThrive LLC: SWOT Analysis
  • Figure 8.44 Jarrow Formulas, Inc.: Overall Product Portfolio
  • Figure 8.45 Jarrow Formulas, Inc.: SWOT Analysis
  • Figure 8.46 Koninklijke DSM N.V.: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.47 Koninklijke DSM N.V.: Overall Financials, 2015-2017
  • Figure 8.48 Koninklijke DSM N.V.: Revenue (by Segment), 2015-2017
  • Figure 8.49 Koninklijke DSM N.V.: Revenue (by Region), 2015-2017
  • Figure 8.50 Koninklijke DSM N.V.: R&D Expenditure, 2015-2017
  • Figure 8.51 Koninklijke DSM N.V.: Global Presence, 2015-2017
  • Figure 8.52 Koninklijke DSM N.V.: SWOT Analysis
  • Figure 8.53 Lallemand Inc.: Overall Product Portfolio
  • Figure 8.54 Lallemand Inc.: SWOT Analysis
  • Figure 8.55 MicroBiome Therapeutics, LLC: Overall Product Portfolio
  • Figure 8.56 MicroBiome Therapeutics, LLC: SWOT Analysis
  • Figure 8.57 Pharmavite LLC: Overall Product Portfolio
  • Figure 8.58 Pharmavite LLC: SWOT Analysis
  • Figure 8.59 Probi AB: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.60 Probi AB: Overall Financials, 2015-2017
  • Figure 8.61 Probi AB: Revenue (by Segment), 2015-2017
  • Figure 8.62 Probi AB: Revenue (by Region), 2015-2017
  • Figure 8.63 Probi AB: R&D Expenditure, 2015-2017
  • Figure 8.64 Probi AB: Revenue Forecast, 2015-2020
  • Figure 8.65 Probi AB: Global Presence, 2015-2017
  • Figure 8.66 Probi AB: SWOT Analysis
  • Figure 8.67 ADM Protexin: Overall Product Portfolio
  • Figure 8.68 ADM Protexin: SWOT Analysis
  • Figure 8.69 Quorum Innovations, LLC: Overall Product Portfolio
  • Figure 8.70 Quorum Innovations, LLC: SWOT Analysis
  • Figure 8.71 Sanofi S.A.: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.72 Sanofi S.A.: Overall Financials, 2015-2017
  • Figure 8.73 Sanofi S.A.: Revenue (by Segment), 2015-2017
  • Figure 8.74 Sanofi S.A.: Revenue (by Region), 2015-2017
  • Figure 8.75 Sanofi S.A.: R&D Expenditure, 2015-2017
  • Figure 8.76 Sanofi S.A.: Revenue Forecast, 2015-2020
  • Figure 8.77 Sanofi S.A.: SWOT Analysis
  • Figure 8.78 The Procter and Gamble Company: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.79 The Procter and Gamble Company: Overall Financials, 2016-2018
  • Figure 8.80 The Procter and Gamble Company: Revenue (by Segment), 2016-2018
  • Figure 8.81 The Procter and Gamble Company: Revenue (by Region), 2016-2018
  • Figure 8.82 Procter and Gamble Company: R&D Expenditure, 2016-2018
  • Figure 8.83 The Procter and Gamble Company: Global Presence, 2016-2018
  • Figure 8.84 The Procter and Gamble Company: SWOT Analysis
  • Figure 8.85 Yakult Honsha Co., Ltd.: Product Portfolio for Human Microbiome Modulators Market
  • Figure 8.86 Yakult Honsha Co., Ltd.: Overall Financials, 2015-2017
  • Figure 8.87 Yakult Honsha Co., Ltd.: Revenue (by Segment), 2015-2017
  • Figure 8.88 Yakult Honsha Co., Ltd.: Revenue (by Region), 2015-2017
  • Figure 8.89 Yakult Honsha Co., Ltd.: R&D Expenditure, 2015-2017
  • Figure 8.90 Yakult Honsha Co., Ltd.: Global Presence, 2015-2017
  • Figure 8.91 Yakult Honsha Co., Ltd.: SWOT Analysis
  • Figure 9.1 Global Human Microbiome Modulators Market Segmentation
  • Figure 9.2 Global Human Microbiome Modulators Market Research Methodology
  • Figure 9.3 Primary Research
  • Figure 9.4 Secondary Research
  • Figure 9.5 Data Triangulation
  • Figure 9.6 Bottom-up Approach (Segment-wise Analysis)
  • Figure 9.7 Top-down Approach (Segment-wise Analysis)
  • Figure 9.8 Assumptions and Limitations
  • Figure 9.9 Considered Factors for Data Prediction and Modeling

Global Human Microbiome Modulators Market to Reach $2.79 Billion by 2023

In the era of precision medicine, the healthcare industry is focused on the development of advanced therapeutics to deliver improved patient care and enhance treatment outcome. The increasing prevalence of chronic disorders and an overall increased demand for preventive medication with minimal/no side-effect are promoting the growth of the human microbiome modulators market. Thereby, the advent of precision medicine approach and development of individualized care regimes are improving quality of life of the patients and reducing economic, societal, and clinical burden.

Presently, product categories within the human microbiome modulators market include probiotics and creams, prebiotics and dietary supplements, and drugs. Till date, the healthcare industry has witnessed a number of successful products modulating the gut microbiome, addressing digestive health. However, successful research substantiating a more inclusive role of the microbiome in human health and diseases, including immune health, women's health, oral health, and other health applications such as skin health, have further drawn the attention of several pharmaceutical companies to venture into this lucrative market by either advancing their respective product portfolios or acquiring companies with immense potentials. Further, several players are now focusing on the development of drugs modulating the microbiome, which is anticipated to enhance the growth of the entire market.

The purpose of the study is to gain a holistic view of the global human microbiome modulators market in terms of various factors influencing the market, including regulatory reforms and technological advancements. The market has been segmented into 'products', 'applications', and 'regions'. The scope of this report is centered upon conducting a detailed study of the products allied with the human microbiome modulators market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape (including pipeline analysis), market share of leading manufacturers, growth potential of each product, application, and region, as well as other vital information with respect to human microbiome modulators market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global human microbiome modulators market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global human microbiome modulators market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of human microbiome modulators market in each region for different applications, and the key strategies and developments by the prominent human microbiome modulators manufacturers.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global human microbiome modulators market?
  • What are the underlying structures resulting in the emerging trends within the human microbiome modulators industry?
  • What was the market value of the leading segments and sub-segments of the global human microbiome modulators market in 2017?
  • How will each segment of the global human microbiome modulators market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2023?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period, 2018- 2023?
  • What are the key developmental strategies which are being implemented by the key players in order to sustain in the competitive market?
  • What are the key product types in human microbiome modulators market? What are the major benefits of each product type?
  • How has the market been segmented on the basis of application? Which application is dominating the global human microbiome modulators market and its reason?
  • Who are the key manufacturers in human microbiome modulators market and what are their contributions?
  • What is the status of each major human microbiome modulators manufacturer with respect to their pipeline?
  • What is the scope of each human microbiome modulators product in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • What are the key regulatory implications in developed and developing regions for human microbiome modulators?
  • What is the growth potential of human microbiome modulators in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • Which human microbiome modulators product type is having most promising growth and in which application type?

The key manufacturers who have been contributing significantly to the human microbiome modulators market include Sanofi S.A., The Procter and Gamble Company, Bayer AG, Koninklijke DSM N.V., E. I. du Pont de Nemours and Company, Yakult Honsha Co., Ltd., BioGaia AB, Probi AB, Chr. Hansen Holding A/S, Ingredion Incorporated, and Immuron Ltd., among others.

Executive Summary

Non-communicable diseases (NCDs) or chronic diseases are a combination of genetic, physiological, behavioral, and environmental factors. Generally tending to be persistent for long durations, NCDs impose immense economic burdens on countries. Given the fact that in 2015, the global healthcare expenditure was estimated by the World Health Organization (WHO) at approximately $7 trillion, the escalating prevalence of NCDs such as diabetes, obesity, cardiovascular diseases, respiratory diseases, and cancers, among others, have significantly driven this expenditure. Expected to reach over $8.5 trillion by 2020, the global health expenditure has been one of the leading causes of economic burden over governments, worldwide.

As of WHO's estimates in 2016, NCDs are responsible for almost 71% deaths globally, killing 41 million people each year. Also, WHO's estimates in 2017 report of a global population of 7.55 billion individuals, a recurrent factor in having direct consequences upon increasing the global disease burden. In addition to the aforementioned estimates, the United Nations Department of Economic and Social Affairs/Population Division estimated that the life expectancy increased from 67.2 years to 70.8 years in the years 2010-2015. In the same report, it was also estimated that approximately 13% of the global population was aged 60 years or above. Compounding these factors, the global economic, clinical, and social burden of NCDs has been escalating at a rapid pace.

Another largely undermined factor for the rising global disease burden is antimicrobial resistance (AMR). Largely a natural phenomenon, antimicrobial resistance is triggered by the excess usage of antibiotics for treatment of diseases with microbial origins. A complex issue of global concern, AMR is majorly driven by human action and perverse incentives. The misuse of antibiotics in the medical, agricultural, and veterinary sectors, which also include inappropriate antibiotic prescription, the overuse of antibiotics in the livestock sector, and insufficient hygiene practices in hospital, all contribute significantly to the rise of AMR.

The advent of precision medicine, a patient-centric treatment approach, is perceived to be promising in driving a paradigm shift in the healthcare industry, facilitating the elimination of uncertainty pertaining to trial and error method of medications, and consequently eliminating unnecessary healthcare spending. As an extension of the precision medicine approach through the Human Genome Project (HGP), the Human Microbiome Project (HMP) was implemented to acquire the 'complete' scope of the human body for precision care. With results published form the Phase 1 of HMP (HMP1), the scientific scope for disease treatment was significantly expanded by the realization of the central role of the microbial population co-existing with the human body. NCDs, being an area direly in need of immediate therapeutic interventions, have naturally become a prevalent scope for microbiome modulation. Consequently, the evolution of human microbiome modulators has come a long way from addressing only digestive complications via dairy-based probiotics to ongoing clinical trials for microbiome-targeting drugs that address a range of diseases indications.

Till 2010, the healthcare industry was largely dominated by synthetic drug modules catering to major disease indications. However, post-2010, precision care has been the prime target for any therapeutic module. With the microbiome's unravelling as a central component of human health and disease, precision care has evolved significantly into becoming a more integrative and more personalized approach. As of 2018, the microbiome modulators market can be seen to have exposure in very few countries. However, with the rapid advancements taking place and an exponential progression in the number of companies entering the space, access to consumers is bound to become easier. The global human microbiome modulators market has been witnessing a steady annual growth rate of approximately 6.08% in past three years (2015-2017), and the market is expected to continue to grow with a double digit CAGR of 16.29% during the forecast period, 2018-2023. Growing at a CAGR of 13.92% during the forecast period of 2018-2023, the probiotics and creams product segment is anticipated to generate a value of $1.66 billion in 2023. However, the global market for drugs is anticipated to grow at the fastest CAGR of 22.26% during the forecast period 2018-2023.

The purpose of the study is to gain a holistic view of the global human microbiome modulators market in terms of various factors such as recent trends and product advancements, influencing the market. The scope of this report is centered upon conducting a detailed study of the products allied with the human microbiome modulators market, which includes various products such as probiotics and creams, prebiotics and dietary supplements, and drugs. However, the market estimation only comprises manufacturers of human microbiome modulators. The human microbiome modulators market is segmented into three different parts namely products, applications, and region. The global market value was estimated using these three different approaches and was validated with one another. These segments are further segmented into several sub-segments to ease the market estimation and to gain a holistic view of the market.

Based on the region, the global human microbiome modulators market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global human microbiome modulators market and was responsible for a 38.47% share of the global market values in 2017. Also, North America is expected to grow the fastest among all other regions with a CAGR of 18.79% during the forecast period 2018-2023.

The key human microbiome modulator manufacturers who have been contributing significantly to the human microbiome modulator market include Sanofi S.A., The Procter and Gamble Company, Bayer AG, Koninklijke DSM N.V., E. I. du Pont de Nemours and Company, Yakult Honsha Co., Ltd., BioGaia AB, Probi AB, Chr. Hansen Holding A/S, and Ingredion Incorporated, among others.

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Classification of Human Microbiome Modulators
  • 1.2 Historical Perspective of Human Microbiome Modulators
  • 1.3 The Human Microbiome Project (2007-2016)
  • 1.4 Impact of Microbiome on Human Physiology
  • 1.5 Global Footprint
  • 1.6 Human Microbiome Modulators: Future Potential

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Iceberg Analysis
  • 2.3 Market Drivers
    • 2.3.1 Rising Geriatric Population
    • 2.3.2 Increasing Incidence of Lifestyle-related Diseases
    • 2.3.3 Gradual Demand for Preventive Medication with Minimal/No Side-Effects
    • 2.3.4 Limited Success Rate of Drugs Targeting Specific Diseases
  • 2.4 Market Restraints
    • 2.4.1 Insufficient Application-Based Research Hindering Market Pull
    • 2.4.2 Lack of Awareness Regarding the Usage of Probiotics and Prebiotics
    • 2.4.3 Non-Harmonized Government Regulations on Probiotics and Prebiotics
  • 2.5 Market Opportunities
    • 2.5.1 Massive Scope for Phenomenal Profits through Venturous Investments
    • 2.5.2 Integrative Industry-Academia Collaboration
    • 2.5.3 Rise of Next-Generation Probiotics
    • 2.5.4 Novel Diagnostic Applications

3 Competitive Landscape

  • 3.1 Key Strategies and Developments
    • 3.1.1 Joint Ventures, Collaborations, and Partnerships
    • 3.1.2 Fundings and Business Expansion Activities
    • 3.1.3 Product Launch
    • 3.1.4 Mergers and Acquisitions
    • 3.1.5 Product Approvals
  • 3.2 Market Share Analysis
  • 3.3 Growth Share Analysis
    • 3.3.1 Growth Share Analysis (by Application)
    • 3.3.2 Growth Share Analysis (by Company)
    • 3.3.3 Growth Share Analysis (by Country)
  • 3.4 Industry Attractiveness
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyer
    • 3.4.3 Threat of New Entrants
    • 3.4.4 Threat of Substitute Products
    • 3.4.5 Intensity of Competitive Rivalry
  • 3.5 Product Pipeline Analysis

4 Regulatory Framework

  • 4.1 Legal Requirements and Framework in the U.S.
    • 4.1.1 For Probiotics
    • 4.1.2 For Prebiotics/Dietary Fibers
    • 4.1.3 For Live Biotherapeutic Products (LBPs)
  • 4.2 Legal Requirements and Framework in Europe
  • 4.3 Legal Requirements and Framework in Asia-Pacific
    • 4.3.1 Japan
    • 4.3.2 China
  • 4.4 Global Microbiome Consortiums

5 Global Human Microbiome Modulators Market (by Product)

  • 5.1 Overview
  • 5.2 Probiotics and Creams
  • 5.3 Prebiotics and Dietary Supplements
  • 5.4 Drugs

6 Global Human Microbiome Modulators Market (by Application)

  • 6.1 Overview
  • 6.2 Digestive Health
  • 6.3 Immune Health
  • 6.4 Women's Health
  • 6.5 Oral Health
  • 6.6 Others

7 Global Human Microbiome Modulators Market (by Region)

  • 7.1 Analysis of Growth Potential of Different Countries: Global Human Microbiome Modulators Market
  • 7.2 North America
    • 7.2.1 The U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Italy
    • 7.3.2 Russia
    • 7.3.3 France
    • 7.3.4 Poland
    • 7.3.5 Germany
    • 7.3.6 The U.K.
    • 7.3.7 Rest-of-Europe
  • 7.4 Asia-Pacific
    • 7.4.1 Japan
    • 7.4.2 Australia
    • 7.4.3 South Korea
    • 7.4.4 China
    • 7.4.5 India
    • 7.4.6 Rest-of-Asia-Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest-of-Latin America
  • 7.6 Rest-of-the-World

8 Company Profiles

  • 8.1 Overview
  • 8.2 Bayer AG
    • 8.2.1 Company Overview
    • 8.2.2 Role of Bayer AG in the Human Microbiome Modulators Market
    • 8.2.3 Financials
    • 8.2.4 Key Insights about Financial Health of the Company
    • 8.2.5 Global Presence
    • 8.2.6 SWOT Analysis
  • 8.3 BioGaia AB
    • 8.3.1 Company Overview
    • 8.3.2 Role of BioGaia AB in the Human Microbiome Modulators Market
    • 8.3.3 Financials
    • 8.3.4 Key Insights about Financial Health of the Company
    • 8.3.5 Global Presence
    • 8.3.6 SWOT Analysis
  • 8.4 Chr. Hansen Holding A/S
    • 8.4.1 Company Overview
    • 8.4.2 Role of Chr. Hansen Holding A/S in the Human Microbiome Modulators Market
    • 8.4.3 Financials
    • 8.4.4 Key Insights about Financial Health of the Company
    • 8.4.5 Global Presence
    • 8.4.6 SWOT Analysis
  • 8.5 DowDuPont Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Role of DowDuPont Inc. in the Human Microbiome Modulators Market
    • 8.5.3 Financials
    • 8.5.4 Key Insights about Financial Health of the Company
    • 8.5.5 Global Presence
    • 8.5.6 SWOT Analysis
  • 8.6 Garden of Life, LLC.
    • 8.6.1 Company Overview
    • 8.6.2 Role of Garden of Life, LLC. In Human Microbiome Modulators Market
    • 8.6.3 SWOT Analysis
  • 8.7 Ingredion Incorporated
    • 8.7.1 Company Overview
    • 8.7.2 Role of Ingredion Incorporated in Human Microbiome Modulators Market
    • 8.7.3 Financials
    • 8.7.4 Key Insights about Financial Health of the Company
    • 8.7.5 Global Presence
    • 8.7.6 SWOT Analysis
  • 8.8 ISOThrive LLC
    • 8.8.1 Company Overview
    • 8.8.2 Role of ISOThrive LLC in the Human Microbiome Modulators Market
    • 8.8.3 SWOT Analysis
  • 8.9 Jarrow Formulas, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Role of Jarrow Formulas, Inc. in Human Microbiome Modulators Market
    • 8.9.3 SWOT Analysis
  • 8.10 Koninklijke DSM N.V.
    • 8.10.1 Company Overview
    • 8.10.2 Role of Koninklijke DSM N.V. in the Human Microbiome Modulators Market
    • 8.10.3 Financials
    • 8.10.4 Key Insights about Financial Health of the Company
    • 8.10.5 Global Presence
    • 8.10.6 SWOT Analysis
  • 8.11 Lallemand Inc.
    • 8.11.1 Company Overview
    • 8.11.2 Role of Lallemand Inc. in Human Microbiome Modulators Market
    • 8.11.3 SWOT Analysis
  • 8.12 MicroBiome Therapeutics, LLC
    • 8.12.1 Company Overview
    • 8.12.2 Role of MicroBiome Therapeutics, LLC in Human Microbiome Modulators Market
    • 8.12.3 SWOT Analysis
  • 8.13 Pharmavite LLC
    • 8.13.1 Company Overview
    • 8.13.2 Role of Pharmavite LLC in Human Microbiome Modulators Market
    • 8.13.3 SWOT Analysis
  • 8.14 Probi AB
    • 8.14.1 Company Overview
    • 8.14.2 Role of Probi AB in the Human Microbiome Modulators Market
    • 8.14.3 Financials
    • 8.14.4 Key Insights about Financial Health of the Company
    • 8.14.5 Global Presence
    • 8.14.6 SWOT Analysis
  • 8.15 Probiotics International Limited (ADM Protexin)
    • 8.15.1 Company Overview
    • 8.15.2 Role of ADM Protexin in Human Microbiome Modulators Market
    • 8.15.3 SWOT Analysis
  • 8.16 Quorum Innovations, LLC
    • 8.16.1 Company Overview
    • 8.16.2 Role of Quorum Innovations, LLC in Human Microbiome Modulators Market
    • 8.16.3 SWOT Analysis
  • 8.17 Sanofi S.A.
    • 8.17.1 Company Overview
    • 8.17.2 Role of Sanofi S.A. in Human Microbiome Modulators Market
    • 8.17.3 Financials
      • 8.17.3.1 Key Insights about Financial Health of the Company
    • 8.17.4 SWOT Analysis
  • 8.18 The Procter and Gamble Company
    • 8.18.1 Company Overview
    • 8.18.2 Role of The Procter and Gamble Company in the Human Microbiome Modulators Market
    • 8.18.3 Financials
    • 8.18.4 Key Insights about Financial Health of the Company
    • 8.18.5 Global Presence
    • 8.18.6 SWOT Analysis
  • 8.19 Yakult Honsha Co., Ltd.
    • 8.19.1 Company Overview
    • 8.19.2 Role of Yakult Honsha Co., Ltd. In Human Microbiome Modulators Market
    • 8.19.3 Financials
    • 8.19.4 Key Insights about Financial Health of the Company
    • 8.19.5 Global Presence
    • 8.19.6 SWOT Analysis

9 Research Scope and Methodology

  • 9.1 Report Scope
  • 9.2 Human Microbiome Modulators Market: Research Methodology
Back to Top
전화 문의
F A Q